Exosomal ligands that are currently of the most therapeutic interest are PD-L1, TNF, FasL, and TRAIL, since their receptors are located on the surfaces of tumor cells, thereby making them potential targets for cancer therapies. This evidence concerns the gene CD274 and neoplasm.